Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06119607
Other study ID # 100144
Secondary ID CIV-LT-23-08-043
Status Recruiting
Phase N/A
First received
Last updated
Start date November 30, 2023
Est. completion date May 2029

Study information

Verified date March 2024
Source Novostia SA
Contact Pomme Boissier, PhD
Phone 0041 58 501 30 33
Email p.boissier@novostia.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective, single arm, exploratory clinical investigation to assess preliminary safety and collect performance and effectiveness data of the TRIFLO Heart Valve.


Description:

Up to 10 Subjects requiring aortic valve replacement of the native valve will be included in this First in Human clinical investigation on the TRIFLO Heart Valve device in Europe. The study is prospective, single-arm-open-label-non-randomized.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date May 2029
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patient is between 18 and 75 years old. - Patient with symptomatic aortic valve disease (stenosis and/or regurgitation) where aortic valve replacement with a mechanical valve is recommended according to the decision of the site heart team and validated by the independent clinical review committee. - Patient with a low surgical mortality risk with EuroSCORE II < 4%. - Patient with echocardiographic Left Ventricular Ejection Fraction (LVEF) > 35% using Transthoracic Echocardiogram (TTE). - Assessment using echocardiography imaging modality of annular suitable for a valve of 21 mm in size and acceptable for the Body Surface Area (BSA) of the patient to avoid any patient prosthesis mismatch. - Participants are able to take low-dose aspirin at a dose of 75 -100 mg daily or have a documented contraindication to aspirin use. - Patient is geographically stable and willing to return to implanting site for follow-up visits up to 5 years. - Patient has been adequately informed of risks and requirements of the clinical investigation and is willing and able to provide informed consent for participation. - In opinion of the Investigator, the patient has a life expectancy of at least 5 years. Exclusion Criteria: - Patient has a pre-existing prosthetic valve (including TAVI) or annuloplasty device or requires replacement or repair of the mitral, pulmonary or tricuspid valve. - Patient is maintained on any permanent or long-term anticoagulant therapy (i.e. any A-fib, deep vein thrombosis, lung embolism, percutaneous coronary intervention (PCI), previous ST-elevation myocardial infarct (STEMI)). - Patient has a history of vascular-related neurological events (TIA, stroke, intracranial bleeding) occurring within 6 months prior to enrollment. - Patient has active endocarditis/myocarditis or other systemic infection within 3 months of the scheduled surgery. - Patient has an additional cardiovascular pathology which would increase surgical risk of morbidity or mortality. - Patient is planning another unrelated surgical procedure outside of the cardiac area within the next 12 months of study device implantation. - Patient has renal insufficiency as determined by creatinine (S-Cr) level as = 1.5 mg/dL or end stage renal disease requiring chronic dialysis at screening visit. - Patient presents hemodynamic or respiratory instability requiring inotropic support, mechanical circulatory support, or mechanical ventilation within 30 days prior to planned valve surgery. - Patient has active, clinically relevant bleeding disorder (documented leukopenia (WBC < 4.0 x 103/µL), acute anemia (Hgb < 10.0 g/dL or 6 mmol/L), thrombocytopenia (platelet count < 100 x 103/µL) or history of bleeding diathesis or coagulopathy). - Patient has had prior organ transplant or is currently an organ transplant candidate. - Patient is currently participating or participated in the last 30 days in another investigational device or drug trial. - Patient who is pregnant, plan to become pregnant during the time of the clinical trial or is lactating or patient of childbearing age not taking any effective method of birth control. - Patient is considered part of vulnerable population (i.e. prison inmates). - Patient with documented history of substance (drug or alcohol) abuse within the last 5 years prior to implantation procedure.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
TRIFLO Heart Valve
Surgical Aortic Valve Replacement - Mechanical Valve

Locations

Country Name City State
Lithuania Vilnius University Hospital Santaros Klinikos Vilnius

Sponsors (2)

Lead Sponsor Collaborator
Novostia SA Veranex

Country where clinical trial is conducted

Lithuania, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety - Mortality Rate of occurrence of all-cause mortality, cardiovascular, non-cardiovascular, and device-related mortality At 12 and 18 months post procedure
Primary Safety - Thrombotic events Rate of valve related thrombotic events Between 3 to 18 months post procedure
Secondary Safety - Major adverse cardiovascular events Rate of occurrence of MACEs 1, 3, 9, 12, 15, 18, 24, 36, 48 and 60 months
Secondary Safety - Thromboembolism events Rate of occurrence of Transient Ischemic Attack (TIA), coronary and/or peripheral embolism 1, 3, 9, 12, 15, 18, 24, 36, 48 and 60 months.
Secondary Safety - Thrombotic events Rate of valve-related thrombotic events 24, 36, 48 and 60 months.
Secondary Safety - Atrial Fibrillation Rate of occurrence of New Onset Atrial Fibrillation 3, 9, 12, 15, 18, 24, 36, 48 and 60 months
Secondary Safety - Endocarditis Rate of occurrence of Endocarditis 1, 3, 9, 12, 15, 18, 24, 36, 48 and 60 months.
Secondary Safety - Hemolysis Rate of occurrence of Hemolysis followed by Plasma free hemoglobin 1, 3, 9, 12, 15, 18, 24, 36, 48 and 60 months.
Secondary Safety - Reoperation Rate of occurrence of Reoperation 1, 3, 9, 12, 15, 18, 24, 36, 48 and 60 months.
Secondary Safety - Structural & Non structural Valve Dysfunction Rate of occurrence of Structural & Non structural Valve Dysfunction 1, 3, 9, 12, 15, 18, 24, 36, 48 and 60 months.
Secondary Safety - Bleeding Rate of occurrence of bleeding classified according to BARC 1, 3, 9, 12, 15, 18, 24, 36, 48 and 60 months.
Secondary Safety - Pacemaker Rate of occurrence New pacemaker implantation due to intervention 3 months
Secondary Safety - All-cause mortality Rate of occurrence of All-cause mortality, cardiovascular, non-cardiovascular, and device related mortality 1, 3, 9, 15, 24, 36, 48 and 60 months
Secondary Safety - Procedural mortality Rate of occurrence of Procedural mortality 1 month.
Secondary Performance - Procedure Rate of initial success, correct positioning of a single TRIFLO Heart Valve into the proper anatomical location. Procedure
Secondary Performance - Hemodynamics Change of hemodynamics compared to baseline followed by mean aortic valve pressure gradient 1, 3, 9, 12, 15, 18, 24, 36, 48 and 60 months
Secondary Performance - Regurgitation Change of regurgitation class (As per VARC 3 Classification Guidelines) compared to baseline 1, 3, 9, 12, 15, 18, 24, 36, 48 and 60 months
Secondary Performance - EOA Change of Effective Orifice Area (EOA) compared to baseline 1, 3, 9, 12, 15, 18, 24, 36, 48 and 60 months
Secondary Performance - Noise Assessment of noise perception - patient survey 3, 9, 12, 15, 18, 24, 36, 48 and 60 months
Secondary Effectiveness - NYHA Change of NYHA Score compared to baseline 1, 3, 9, 12, 18, 24, 36, 48 and 60 months
Secondary Effectiveness - QoL Change of Quality-of-life Score using KCCQ-12 questionnaires, compared to baseline 1, 3, 9, 12, 18, 24, 36, 48 and 60 months
Secondary Effectiveness - 6MWT Functional Assessment in 6-min walk test 3, 9, 12, 18, 24, 36, 48 and 60 months
Secondary Usability Assessment of device handling ease by the physician - survey Procedure
See also
  Status Clinical Trial Phase
Recruiting NCT04149600 - Identification of Genetic Causes of Calcific Aortic Valve Disease
Recruiting NCT06001489 - The Effects of 360-degree Virtual Reality on Pre-procedural Anxiety in Patients Awaiting Elective Cardiac Surgery Involving a Sternotomy N/A
Not yet recruiting NCT04430972 - Immune Responsiveness and Outcome After Aortic Valve Surgery (Measure)
Completed NCT02467062 - Implementation of Non-size Markers Derived From 4D Flow MRI of Patients With Aortic Disease. N/A
Not yet recruiting NCT02221921 - Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI N/A
Terminated NCT02128841 - Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve. Phase 2
Active, not recruiting NCT01194362 - A Study to Identify Differences in Gene Expression in Patients With Bicuspid and Tricuspid Valve Disease
Not yet recruiting NCT05975567 - Deploying Novel Imaging Modalities Towards a Three-dimensional (3D) CARDIOvascular PATHology
Recruiting NCT06025149 - The Study on the Use of "UniLine" Bioprosthesis in the Treatment of Isolated Aortic and Mitral Valve Diseases
Completed NCT05082337 - The SAVVY Guidewire in Transcatheter Aortic Valve Replacement Procedures N/A
Completed NCT05193760 - Robustness Check of Placement and Measurement Algorithms for Blood Flow Measurement on Common Carotid Artery
Not yet recruiting NCT05941455 - A Prospective Multicenter Pivotal Study to Evaluate Safety and Effectiveness of Venus-Neo Surgical Aortic Valve N/A
Active, not recruiting NCT04950192 - Philips Intracardiac Echocardiography (ICE) Clinical Registry
Active, not recruiting NCT03924661 - SJM Masters HP 15mm Rotatable Mechanical Heart Valve as Aortic Valve Replacement Therapy
Completed NCT04073875 - 18F-GP1 PET-CT to Detect Bioprosthetic Aortic Valve Thrombosis
Recruiting NCT03121053 - Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement Phase 4
Completed NCT02000544 - Clinical Evaluation of a Modular Extracorporeal Circulation Circuit N/A
Completed NCT02688153 - EDWARDS INTUITY Valve System CADENCE Study N/A
Completed NCT02981004 - PAR I - Patient-to-Annulus Relation I
Recruiting NCT06126367 - Assessment of Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic Cardiovascular Disease/Aortic Valve Disease